These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 21920241)

  • 21. Risk factors for facial melasma in women: a case-control study.
    Handel AC; Lima PB; Tonolli VM; Miot LD; Miot HA
    Br J Dermatol; 2014 Sep; 171(3):588-94. PubMed ID: 24749693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of melasma with topical agents, peels and lasers: an evidence-based review.
    Rivas S; Pandya AG
    Am J Clin Dermatol; 2013 Oct; 14(5):359-76. PubMed ID: 23881551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma.
    Ortonne JP; Arellano I; Berneburg M; Cestari T; Chan H; Grimes P; Hexsel D; Im S; Lim J; Lui H; Pandya A; Picardo M; Rendon M; Taylor S; Van Der Veen JP; Westerhof W
    J Eur Acad Dermatol Venereol; 2009 Nov; 23(11):1254-62. PubMed ID: 19486232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pathogenesis of melasma and implications for treatment.
    Artzi O; Horovitz T; Bar-Ilan E; Shehadeh W; Koren A; Zusmanovitch L; Mehrabi JN; Salameh F; Isman Nelkenbaum G; Zur E; Sprecher E; Mashiah J
    J Cosmet Dermatol; 2021 Nov; 20(11):3432-3445. PubMed ID: 34411403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and awareness of melasma during pregnancy.
    Moin A; Jabery Z; Fallah N
    Int J Dermatol; 2006 Mar; 45(3):285-8. PubMed ID: 16533230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Physiopathology of melasma].
    Miot LD; Miot HA; Silva MG; Marques ME
    An Bras Dermatol; 2009; 84(6):623-35. PubMed ID: 20191174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperpigmentation: an overview of the common afflictions.
    Cayce KA; McMichael AJ; Feldman SR
    Dermatol Nurs; 2004 Oct; 16(5):401-6, 413-6; quiz 417. PubMed ID: 15624705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melasma.
    Lee BW; Schwartz RA; Janniger CK
    G Ital Dermatol Venereol; 2017 Feb; 152(1):36-45. PubMed ID: 27589484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Melasma treatment: A novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor.
    Cohen PR
    Med Hypotheses; 2017 Apr; 101():1-5. PubMed ID: 28351480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melasma: insights and perspectives.
    Jadotte YT; Schwartz RA
    Acta Dermatovenerol Croat; 2010; 18(2):124-9. PubMed ID: 20624364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of hydroquinone-resistant melasma using topical methimazole.
    Malek J; Chedraoui A; Nikolic D; Barouti N; Ghosn S; Abbas O
    Dermatol Ther; 2013; 26(1):69-72. PubMed ID: 23384022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of melasma with thyroid autoimmunity and other thyroidal abnormalities and their relationship to the origin of the melasma.
    Lutfi RJ; Fridmanis M; Misiunas AL; Pafume O; Gonzalez EA; Villemur JA; Mazzini MA; Niepomniszcze H
    J Clin Endocrinol Metab; 1985 Jul; 61(1):28-31. PubMed ID: 3923030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Dermocosmetic management of hyperpigmentations].
    Guerrero D
    Ann Dermatol Venereol; 2012 Nov; 139 Suppl 3():S115-8. PubMed ID: 23260519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Energy-based device treatment of melasma: An update and review of the literature.
    Dunbar S; Posnick D; Bloom B; Elias C; Zito P; Goldberg DJ
    J Cosmet Laser Ther; 2017 Feb; 19(1):2-12. PubMed ID: 27594445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of fibroblast-derived factors in the pathogenesis of melasma.
    Byun JW; Park IS; Choi GS; Shin J
    Clin Exp Dermatol; 2016 Aug; 41(6):601-9. PubMed ID: 27416970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of patient characteristics on illness perception and sun protection behaviors in melasma.
    Nazli EC; Avcı C; Akarsu S
    J Cosmet Dermatol; 2022 Dec; 21(12):7107-7115. PubMed ID: 36136352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physical signs for the general dental practitioner. Case 45. Melasma.
    Bain S
    Dent Update; 2007 Jun; 34(5):316. PubMed ID: 17624149
    [No Abstract]   [Full Text] [Related]  

  • 38. Melasma in a transgender woman.
    Garcia-Rodriguez L; Spiegel JH
    Am J Otolaryngol; 2018; 39(6):788-790. PubMed ID: 30104074
    [No Abstract]   [Full Text] [Related]  

  • 39. Topical treatments for melasma and postinflammatory hyperpigmentation.
    Lynde CB; Kraft JN; Lynde CW
    Skin Therapy Lett; 2006 Nov; 11(9):1-6. PubMed ID: 17075653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Melasma treated with intense pulsed light.
    Zoccali G; Piccolo D; Allegra P; Giuliani M
    Aesthetic Plast Surg; 2010 Aug; 34(4):486-93. PubMed ID: 20225000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.